Menu
Not yet recruiting NCT07323394

Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective

Observational Atopic Dermatitis Eczema Atopic Dermatitis Eczema Caregiver

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: No Intervention: Observational Cohort.
Who it may be relevant to
Registry conditions: Atopic Dermatitis, Eczema Atopic Dermatitis, Eczema, Caregiver. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This study will address this gap by providing comprehensive data on disease burden from a caregiver perspective in a Canadian population, ultimately supporting improved clinical decision-making and healthcare resource allocation.

Interventions

  • Other No Intervention: Observational Cohort
    No specific intervention is assess in this study. Observational cohort.

Primary outcome measures

  • To estimate work productivity loss in caregivers of children with mild or moderate atopic dermatitis. [Time frame: At recruitment]
Secondary outcome measures (1)
  • To estimate family burden of mild to moderate atopic dermatitis in children, as reported by caregivers [Time frame: At recruitment]

Eligibility criteria

Inclusion criteria

  • Aged ≥18 years;
  • Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis;
  • Able to read and understand French or English;
  • Willing and able to provide written informed consent.

Exclusion criteria

  • Caregivers whose child has been diagnosed with severe atopic dermatitis ;
  • Caregivers whose child is currently treated with oral or topical Janus Kinase Inhibitor);
  • Caregivers whose child is currently participating in a clinical trial for atopic dermatitis;
  • Other parent or caregiver within the household of the child with atopic dermatitis.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07323394 · PROxy96AD

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗